---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-25-000004"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:42:36.617060+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arcutis reports Q4 product revenue ~$63M (+366% YoY); FY2024 ~$160M (+449% YoY)

## Summary
- Preliminary Q4 2024 product revenue ~$63M, up ~366% vs Q4 2023 and ~41% vs Q3 2024.
- Full-year 2024 product revenue ~$160M, up ~449% compared to 2023, driven by ZORYVE demand.
- Cash and marketable securities ~$229M as of Dec 31, 2024; total liquidity ~$329M after $100M debt repayment and re-draw option.
- Gross-to-net similar to prior quarter; robust unit growth across portfolio.
- Company to report complete Q4/FY2024 results and host conference call on Feb 25, 2025.

## SEC filing metadata
- accession: 0001787306-25-000004
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730625000004/0001787306-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730625000004/arqt-20250112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-25-000004
- JSON: https://secwatch.observer/filing/0001787306-25-000004.json
- Plain text: https://secwatch.observer/filing/0001787306-25-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.